Home Newsfeeds Needham Reiterates Buy on Microchip Technology, Maintains $110 Price Target

Needham Reiterates Buy on Microchip Technology, Maintains $110 Price Target

Needham analyst Rajvindra Gill reiterates Microchip Technology (NASDAQ:MCHP) with a Buy and maintains $110 price target.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Needham analyst Rajvindra Gill reiterates Microchip Technology (NASDAQ:MCHP) with a Buy and maintains $110 price target.

Goldman Sachs Initiates Coverage On Enhabit with Neutral Rating, Announces Price Target of $15

By Benzinga Newsdesk

March 16, 4:57 AM

Goldman Sachs analyst Jamie Perse initiates coverage on Enhabit (NYSE:EHAB) with a Neutral rating and announces Price Target of $15.

EHAB

Recent Report Shows That Rep. Carol Miller Bought Up to $150K Worth of iShares MSCI Emerging Markets ex China ETF Stock

By Benzinga Insights

November 10, 11:05 AM

The Office of West Virginia Representative Carol Miller has reported a purchase of iShares MSCI Emerging Markets ex…

EMXC

Amryt Receives Orphan Drug Designation From The FDA For Mycapssa For The Treatment Of Carcinoid Syndrome

By Benzinga Newsdesk

July 14, 7:03 AM

Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that the US Food and Drug

AMYT

Analyst Ratings

Analyst Ratings for Scorpio Tankers

By Benzinga Insights

January 12, 3:00 PM

Within the last quarter, Scorpio Tankers (NYSE:STNG) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

STNG

Needham Reiterates Buy on Microchip Technology, Maintains $110 Price Target

Related Posts

Goldman Sachs Initiates Coverage On Enhabit with Neutral Rating, Announces Price Target of $15

Recent Report Shows That Rep. Carol Miller Bought Up to $150K Worth of iShares MSCI Emerging Markets ex China ETF Stock

Amryt Receives Orphan Drug Designation From The FDA For Mycapssa For The Treatment Of Carcinoid Syndrome

Analyst Ratings for Scorpio Tankers